MAPK3 and glioblastoma: Patient analysis revealed that in patients with recurrent glioblastoma, BRAF/PTPN11 mutations were enriched in 30% of those who responded to PD-1 blockade.168 ERK1/2 phosphorylation further predicted survival outcomes in those who received PD-1 blockade.169,170